Viking Therapeutics (VKTX) to Release Quarterly Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX) is anticipated to release its earnings data after the market closes on Wednesday, February 5th. Analysts expect Viking Therapeutics to post earnings of ($0.28) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Viking Therapeutics Price Performance

VKTX opened at $32.75 on Monday. The business has a 50 day moving average price of $42.17 and a two-hundred day moving average price of $54.58. The company has a market capitalization of $3.65 billion, a price-to-earnings ratio of -35.21 and a beta of 0.95. Viking Therapeutics has a 1-year low of $22.51 and a 1-year high of $99.41.

Analysts Set New Price Targets

VKTX has been the subject of several research analyst reports. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th. Piper Sandler assumed coverage on shares of Viking Therapeutics in a report on Monday, December 2nd. They issued an “overweight” rating and a $74.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $102.00 target price on shares of Viking Therapeutics in a report on Friday, January 17th. B. Riley started coverage on Viking Therapeutics in a research report on Friday, November 22nd. They set a “buy” rating and a $109.00 price objective for the company. Finally, William Blair restated an “outperform” rating on shares of Viking Therapeutics in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Viking Therapeutics presently has an average rating of “Buy” and a consensus price target of $106.75.

Insider Buying and Selling

In related news, Director Lawson Macartney sold 2,000 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $68.67, for a total transaction of $137,340.00. Following the completion of the sale, the director now directly owns 47,965 shares in the company, valued at approximately $3,293,756.55. This trade represents a 4.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Marianna Mancini sold 54,215 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $42.75, for a total value of $2,317,691.25. Following the completion of the transaction, the chief operating officer now owns 374,134 shares in the company, valued at $15,994,228.50. This trade represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 301,014 shares of company stock valued at $12,920,189. Corporate insiders own 4.70% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.